NCT05154370View on ClinicalTrials.gov

China National Registry of Neuro-Inflammatory Diseases

RecruitingOBSERVATIONAL
Enrollment

10,000

Participants

Timeline

Start Date

December 15, 2021

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Multiple SclerosisNMO Spectrum DisorderClinically Isolated SyndromeCNS Demyelinating Autoimmune DiseasesAcute Disseminated EncephalomyelitisPrimay Angiitis of the Central Nervous SystemAutoimmune Glial Fibrillary Acidic Protein Astrocytopathy
Interventions
DRUG

Intravenous steroid

This study does not limit treatment methods. Patients commonly use high-dose intravenous steroid therapy (HD-S) during acute stage. Immunomodulatory therapies are necessary for the remission stage. All drugs are used in accordance with relevant guidelines.

Trial Locations (1)

100069

RECRUITING

Beijing Tiantan Hospital, Beijing

All Listed Sponsors
lead

Beijing Tiantan Hospital

OTHER